Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2026
Purpose: Disclosure of an investor presentation (Exhibit 99.1) under Regulation FD (Item 7.01) to be distributed to institutional investors and analysts.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to announce the availability of a corporate presentation and does not contain audited financial statements or specific financial data points.
Material Changes
No material changes to financial performance or operations are detailed in the text of this filing. The document references an attached presentation (Exhibit 99.1) which may contain updates, but the content of that presentation is not included in the provided text.
Guidance, Outlook, and Risks
- Management Commentary: The Company is furnishing an investor presentation to update stakeholders. The text notes that this information may be amended or updated in future filings.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Availability: The presentation is available on the Company's website, though the Company reserves the right to discontinue availability at any time.
Key Facts for Investor Verification
- Verify the content of the attached "Corporate Presentation dated February 2026" (Exhibit 99.1) for specific financial data and strategic updates, as the 8-K text itself contains no numbers.
- Confirm the current availability of the presentation on the Company's investor relations website.
- Note that the disclosure is subject to change and may be superseded by future filings.